ClinicalTrials.gov
public full text
Public Domain
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
This phase II trial is studying how well erlotinib works in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia#1164477
- Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma#1088178
- Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma#862515
- Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma#904803
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial#140997
Record · ID 1151005
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive